BIONANO GENOMICS INC (BNGO) Fundamental Analysis & Valuation

NASDAQ:BNGO • US09075F4046

Current stock price

1.21 USD
0 (0%)
At close:
1.22 USD
+0.01 (+0.83%)
After Hours:

This BNGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BNGO Profitability Analysis

1.1 Basic Checks

  • In the past year BNGO has reported negative net income.
  • BNGO had a negative operating cash flow in the past year.
  • In the past 5 years BNGO always reported negative net income.
  • In the past 5 years BNGO always reported negative operating cash flow.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -35.87%, BNGO is doing worse than 80.36% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -59.42%, BNGO is doing worse than 71.43% of the companies in the same industry.
Industry RankSector Rank
ROA -35.87%
ROE -59.42%
ROIC N/A
ROA(3y)-96.8%
ROA(5y)-70.55%
ROE(3y)-205.95%
ROE(5y)-138.5%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • BNGO has a Gross Margin (46.25%) which is comparable to the rest of the industry.
  • BNGO's Gross Margin has improved in the last couple of years.
  • BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.28%
GM growth 5Y7.25%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BNGO Health Analysis

2.1 Basic Checks

  • BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BNGO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BNGO has less shares outstanding
  • BNGO has a worse debt/assets ratio than last year.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -14.16, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -14.16, BNGO is doing worse than 92.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that BNGO is not too dependend on debt financing.
  • BNGO's Debt to Equity ratio of 0.08 is fine compared to the rest of the industry. BNGO outperforms 64.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -14.16
ROIC/WACCN/A
WACC17.58%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • BNGO has a Current Ratio of 1.98. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
  • BNGO has a Current ratio of 1.98. This is in the lower half of the industry: BNGO underperforms 62.50% of its industry peers.
  • BNGO has a Quick Ratio of 1.74. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.74, BNGO is in line with its industry, outperforming 44.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.74
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BNGO Growth Analysis

3.1 Past

  • BNGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.31%, which is quite impressive.
  • BNGO shows a decrease in Revenue. In the last year, the revenue decreased by -7.37%.
  • BNGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.38% yearly.
EPS 1Y (TTM)94.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.81%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y0.84%
Revenue growth 5Y27.38%
Sales Q2Q%-2.6%

3.2 Future

  • Based on estimates for the next years, BNGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.14% on average per year.
  • BNGO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.18% yearly.
EPS Next Y46.65%
EPS Next 2Y31.86%
EPS Next 3Y23.65%
EPS Next 5Y17.14%
Revenue Next Year13.86%
Revenue Next 2Y23.86%
Revenue Next 3Y24.35%
Revenue Next 5Y28.18%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BNGO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNGO. In the last year negative earnings were reported.
  • Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BNGO's earnings are expected to grow with 23.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3Y23.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNGO Dividend Analysis

5.1 Amount

  • BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNGO Fundamentals: All Metrics, Ratios and Statistics

BIONANO GENOMICS INC

NASDAQ:BNGO (4/24/2026, 5:20:02 PM)

After market: 1.22 +0.01 (+0.83%)

1.21

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-23
Earnings (Next)05-12
Inst Owners10.6%
Inst Owner Change0%
Ins Owners2.92%
Ins Owner Change0%
Market Cap13.42M
Revenue(TTM)28.51M
Net Income(TTM)-26.39M
Analysts80
Price Target5.61 (363.64%)
Short Float %12.06%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.14%
Min EPS beat(2)18.39%
Max EPS beat(2)97.9%
EPS beat(4)4
Avg EPS beat(4)49.54%
Min EPS beat(4)18.39%
Max EPS beat(4)97.9%
EPS beat(8)6
Avg EPS beat(8)2.94%
EPS beat(12)7
Avg EPS beat(12)4.31%
EPS beat(16)8
Avg EPS beat(16)-1.24%
Revenue beat(2)1
Avg Revenue beat(2)2.19%
Min Revenue beat(2)-0.74%
Max Revenue beat(2)5.12%
Revenue beat(4)2
Avg Revenue beat(4)0.64%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)3.75%
Revenue beat(12)7
Avg Revenue beat(12)2.59%
Revenue beat(16)10
Avg Revenue beat(16)2.4%
PT rev (1m)-26.67%
PT rev (3m)-26.67%
EPS NQ rev (1m)8.06%
EPS NQ rev (3m)8.06%
EPS NY rev (1m)30.25%
EPS NY rev (3m)30.25%
Revenue NQ rev (1m)-16.67%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)-8.37%
Revenue NY rev (3m)-8.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-4.76
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS2.57
BVpS4.01
TBVpS3.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -35.87%
ROE -59.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.25%
FCFM N/A
ROA(3y)-96.8%
ROA(5y)-70.55%
ROE(3y)-205.95%
ROE(5y)-138.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.28%
GM growth 5Y7.25%
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.74
Altman-Z -14.16
F-Score4
WACC17.58%
ROIC/WACCN/A
Cap/Depr(3y)4.29%
Cap/Depr(5y)12.34%
Cap/Sales(3y)1.67%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.81%
EPS Next Y46.65%
EPS Next 2Y31.86%
EPS Next 3Y23.65%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y0.84%
Revenue growth 5Y27.38%
Sales Q2Q%-2.6%
Revenue Next Year13.86%
Revenue Next 2Y23.86%
Revenue Next 3Y24.35%
Revenue Next 5Y28.18%
EBIT growth 1Y56.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.28%
OCF growth 3YN/A
OCF growth 5YN/A

BIONANO GENOMICS INC / BNGO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIONANO GENOMICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to BNGO.


Can you provide the valuation status for BIONANO GENOMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIONANO GENOMICS INC (BNGO). This can be considered as Overvalued.


What is the profitability of BNGO stock?

BIONANO GENOMICS INC (BNGO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BNGO stock?

The Earnings per Share (EPS) of BIONANO GENOMICS INC (BNGO) is expected to grow by 46.65% in the next year.